Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic Neuroendocrine Tumors
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Temozolomide
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Sep 2017 Planned number of patients changed from 39 to 33.
- 13 Sep 2017 Status changed from not yet recruiting to recruiting.
- 27 Oct 2016 New trial record